SMAD family member proteins (SMAD) (SMAD)

SMAD family member proteins are a group of intracellular signal transducers that mediate the signaling of the transforming growth factor-beta (TGF-beta) superfamily (Source: UniProt). These proteins are categorized into three functional groups: receptor-regulated SMADs (R-SMADs: SMAD1, 2, 3, 5, 8/9), common-partner SMADs (Co-SMAD: SMAD4), and inhibitory SMADs (I-SMADs: SMAD6, 7) (Source: PubMed, PMID: 22561030). Upon activation of TGF-beta or bone morphogenetic protein (BMP) receptors, R-SMADs are phosphorylated, form complexes with SMAD4, and translocate to the nucleus to regulate the transcription of target genes involved in cell proliferation, differentiation, and apoptosis (Source: NIH, Gene ID: 4089). Dysregulation of SMAD signaling is a hallmark of various pathologies, including many types of cancer where SMAD4 often acts as a tumor suppressor, and fibrotic diseases where SMAD3 promotes excessive extracellular matrix production (Source: Nature Reviews Molecular Cell Biology). In oncology, the loss of SMAD4 is a critical biomarker for progression in pancreatic and colorectal cancers (Source: StatPearls). Therapeutic strategies targeting the SMAD pathway primarily focus on small molecule inhibitors of R-SMAD phosphorylation or antisense oligonucleotides, though many current clinical candidates target the upstream TGF-beta receptors (Source: Journal of Clinical Investigation). Challenges in targeting SMADs include their pleiotropic nature and the potential for significant off-target effects on normal tissue homeostasis and immune function (Source: PubMed, PMID: 28115516).

Other names

Mothers against decapentaplegic homologMADHMADDPC4 (for SMAD4)JV18JP18Hmad

Inhibition of R-SMAD phosphorylation, blockade of SMAD-SMAD complex formation, inhibition of nuclear translocation, and modulation of SMAD-DNA binding (Source: PubMed).